No 15-year survival benefit associated with primary ADT in older men

In another paper just published on-line in JAMA Internal Medicine this week, the authors have provided additional data indicating — once again — the lack of any value of primary androgen deprivation therapy (ADT) in the management of early-stage, localized prostate cancer among older patients. … READ MORE …

The PATCH study will continue to accrue patients in the UK

The Prostate Adenocarcinoma: TransCutaneous Hormones or PATCH trial is an ongoing study in the UK that was designed (in a series of stages) to determine whether estrogen patch therapy might be at least no worse than (i.e., “non-inferior” to) LHRH agonist therapy in suppressing androgens to castrate level. … READ MORE …

What’s being presented at ASCO this year: II

A “first-of-its kind” quality of life study to be presented at ASCO this year is a year-long, randomized, three-arm trial of the value of “purposeful” physical exercise in the management of men on androgen deprivation therapy (ADT) for progressive prostate cancer. … READ MORE …

Deferred or immediate initiation of ADT in patients with PSA-only relapse

Abstracts of all papers to be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) were made available for pre-meeting review yesterday. A paper on the appropriate timing of initiation of androgen deprivation therapy (ADT) was featured by ASCO in its related news conference. … READ MORE …

Efficacy of continuous ADT and correlation to nadir serum T levels

We had “missed” a poster presented at the recent meeting of the European Urology Association that appears to “put to bed” — in a positive fashion — the question of a relationship between nadir serum testosterone (T) levels in men on continuous androgen deprivation therapy (ADT) and the long-term effectiveness of continuous ADT. … READ MORE …

Primary ADT ineffective for most men with early stage prostate cancer

Data from a large, retrospective study, reported in the Journal of Clinical Oncology, suggest something that many expert clinicians and patients have long suspected … that early use of androgen deprivation therapy (ADT) alone is not an effective treatment for most men with early stage prostate cancer. … READ MORE …

Supervised exercise and prevention of ADT-related side effects

A small, randomized trial in a group of 60+ Australian patients has demonstrated that a supervised exercise program started at the same time as initiation of androgen deprivation therapy (ADT) can have multiple beneficial results, including (at least temporary) avoidance of known side effects of ADT. … READ MORE …

AR gene amplification and risk for CRPC

An article just published in the British Journal of Cancer, has proposed that androgen receptor (AR) gene amplification may be a prime cause of treatment failure in a subset of men with progressive prostate cancer. … READ MORE …

Does normal expression of SPOP prevent development of many prostate cancers?

Researchers from the Mayo Clinic in Rochester, MN, are claiming that they have made a series of four important discoveries related to the role of a protein called “speckle-type POZ protein” (SPOP) and its involvement in the development of prostate cancer. … READ MORE …

The androgen receptor pathway … this morning in San Francisco

So today’s early morning session of the GU Oncology meeting was highly focused on the evolution of newer therapies affecting the androgen receptor pathways in the treatment of advanced and progressive forms of prostate cancer. … READ MORE …

Quality of life in the first 2 years on ADT for non-metastatic patients

A forthcoming paper in the Journal of Urology has attempted to quantify the effects of androgen deprivation therapy (ADT) on the mental and emotional well-being of men with non-metastatic prostate cancer. … READ MORE …

Baseline serum androgen levels and responses to abiraterone acetate

Baseline levels of serum androgens were predictive for clinical response to treatment in the Phase III clinical trial of abiraterone acetate in men with chemotherapy-refractory, metastatic, castration-resistant prostate cancer (mCRPC), according to a new article in the Journal of Clinical Oncology. … READ MORE …

Prevention of bone-related and metabolic complications of treatment for men on ADT

A new article from an Australian clinical research group in the journal Andrology addresses “the effectiveness of implementing standardized guidelines to mitigate metabolic and bone side effects of androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer.” … READ MORE …

Radiation therapy, neoadjuvant ADT, and initial PSA response

New data from Zelefsky and his colleagues at Memorial Sloan-Kettering Cancer Center suggest that men who respond well to neoadjuvant androgen deprivation therapy (ADT) have better long-term outcomes after radiation therapy given with curative intent for localized prostate cancer. … READ MORE …

Australian researchers identify “castration-tolerant cancer-repopulating cells” in mouse model

According to a media release issued earlier today in Australia, “a study led by Monash University researchers has found prostate cancer cells that survive androgen withdrawal treatment. Previously unidentified, these cells are potential targets for future treatments.” … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,115 other followers